ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 7,803	$ 2,016
Accumulated deficit	1,566,265		$ 1,527,033
Cash and cash equivalents, and investment securities	139,700
BRIUMVI (Ublituximab)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 7,800